frequently than in standard 22q11DS). 2 Only a single case of D-22q11DS exhibiting interrupted aortic arch type B has been reported 9 and this defect, which is the most specific for the typical deletion, is not normally associated with D-22q11DS (Online Table I ).
22q11 microdeletions result in hemizygosity for multiple genes (≈30 in the typical deleted region) and thus the pathology may result from complex genetic interactions. To date, 3 genes have been implicated. 2 The transcription factor TBX1 (within the LCR-A/B interval) seems to be the major determinant of the classical 22q11DS clinical phenotype. 10 Transgenic expression of a bacterial artificial chromosome containing TBX1 can rescue a mouse model of 22q11DS. 11 Mice heterozygous for Tbx1 exhibit fourth arch artery defects although many phenotypes affecting the heart itself, such as common arterial trunk (CAT), are only seen in the homozygous condition. 12, 13 This suggests that an interaction between multiple genes may be required for the full phenotype. CRKL (within the LCR-C/D interval) encodes an adaptor protein, which is required for normal fibroblast growth factor (FGF)8 signaling responses. Crkl -/-mice exhibit VSD and a low incidence of pharyngeal arch artery defect, 14 which becomes more penetrant when Fgf8 is reduced to hemizygosity, 15 but Crkl +/-mice do not show evidence of haploinsufficiency. Rather, it seems Crkl hemizygosity may modify the Tbx1 haploinsufficient phenotype via FGF and effects on retinoic acid signaling. 16 MAPK1 (within the LCR-D/E interval) encodes a mitogen-activated protein kinase. Targeting of Mapk1 in the neural crest lineage demonstrated late embryonic lethality and a range of craniofacial and cardiac defects, including a 40% incidence of VSD, 17 but no haploinsufficiency was reported for this allele.
HIC2 is located in an island of nonrepetitive DNA at the distal end of LCR-D ( Figure 1B ) and is lost in the majority of D-22q11DS deletions, as well as in a minority of typical deletions (between 4% and 15% of cases). [18] [19] [20] HIC2 encodes a putative transcription factor and is related to the tumor suppressor HIC1, hypermethylated in cancer. 21 Importantly, Hic1 has been shown to have a haploinsufficient tumorigenic phenotype in mice 22 and has been proposed to have a role in the facial phenotype of Miller-Dieker syndrome. 23, 24 Hic1 -/-mice die at birth and have acrania, exencephaly, cleft palate, limb abnormalities, and omphalocele indicating that the gene is required for normal development. 23 We hypothesized that HIC2 may be important in embryonic cardiovascular development. Here, we use a genetrap reporter allele of Hic2 to demonstrate expression in the heart throughout the critical period of morphogenesis. We show that loss of Hic2 is embryonic lethal and demonstrates a haploinsufficient cardiac phenotype. Conditional targeting of Hic2 reveals a requirement in the Nkx2.5+ and Mesp1+ lineages. Microarray analysis reveals upregulation of a program of ectopic expression in the absence of Hic2.
Methods
Detailed Methods are available in the Online Data Supplement.
Mouse Genetics
All animal maintenance, husbandry, and procedures were performed in accordance with Home Office regulations. Details of mice used in this study are provided in the Online Data Supplement.
Three-Dimensional Imaging of Embryonic Hearts
Embryos for imaging were harvested at embryonic day (E) 15.5, an age when formation of the ventricular septum should be complete. After fixation, embryos were embedded in agarose and imaged either by optical projection tomography using a Bioptonics scanner (MRC Technology, Edinburgh, United Kingdom) or by MRI using an 11.7 Tesla vertical magnet (Magnex Scientific, Oxon, United Kingdom) interfaced to a Bruker Avance spectrometer (Bruker Medical, Ettlingen, Germany) as previously reported. 25, 26 Optical projection tomography images were viewed using Fiji ImageJ (http://fiji.sc/Fiji), whereas 3-dimensional (3D) reconstructions of MRI data were performed using Amira (FEI Visualization Sciences Group, Merignac, France).
Microarray Analysis and Reverse TranscriptasePolymerase Chain Reaction
Analysis was performed on isolated hearts. Probes were hybridized to the Mouse Exon 1.0 ST whole transcript array genechip (Affymetrix).
Results
Hemizygous loss of HIC2 is associated with congenital cardiac disease. We first reviewed the D-22q11DS literature to determine whether loss of HIC2 is associated with congenital cardiac disease. These data are summarized in Table 1 , whereas the full data set with references is provided in Online Table  I . We identified 51 reported cases of D-22q11DS although breakpoint mapping data were reported for only 40 of these cases. Breakpoints within LCR-D usually occur proximal to HIC2, but sometimes are distal [18] [19] [20] and in a few cases have been mapped to the first intron of HIC2 itself, [27] [28] [29] ( Figure 1B ) thus HIC2 is normally, but not always, lost in D-22q11DS. Thirty-three of the 40 mapped D-22q11DS deletions are hemizygous for HIC2 ( Table 1 ). The frequency of cardiac phenotypes in the group lacking HIC2 is close to that of the D-22q11DS group as a whole (61% versus 63%; Table 1 ). The most common defect is VSD (30%) followed by atrial septal defect (ASD; 12%), then persistent ductus arteriosus (DA; 9%), and then CAT (9%).
Distal deletions with a proximal breakpoint at either LCR-E or LCR-F have a significantly reduced frequency of cardiac defects (22%; P=0.03; Table 1 ), suggesting that a gene critical for normal cardiac development lies within the LCR-D/E interval. This interval includes both HIC2 and MAPK1 ( Figure 1A ). To differentiate the relative contributions of HIC2 and MAPK1 to the phenotype, it requires the analysis of deletions containing only 1 of these genes. The occurrence of a deletion, including HIC2 but not MAPK1, would require a non-LCR-mediated break, which is a rare event, and such deletions have not been reported. However, because of Table 3 ) describe qualitative differences between 22q11DS and D-22q11DS. In particular, VSD is far more common in D-22q11DS (63% versus 13% to 14%), whereas CAT, persistent DA, and ASD are all also more common. Figures of Fagerberg et al 5 are similar to the group in our analysis that includes HIC2 and is different from that excluding HIC2 (eg, CAT is not seen in this latter group).
In summary, human genetic evidence does not definitively prove a role for HIC2 in the pathology of D-22q11DS but suggests that a second gene within the LCR-D/E interval in addition to MAPK1 may play a role in modifying the phenotype. We present evidence below from mouse work to support a role for HIC2.
Hic2 Is Expressed in the Mouse Heart Throughout Morphogenesis
To test the hypothesis that Hic2 is important for cardiac development, we obtained a mouse genetrap model in which β-galactosidase is expressed from the Hic2 locus (Hic2 GT ). β-galactosidase staining of heterozygous embryos revealed reporter expression throughout the major period of cardiac morphogenesis. Early in embryogenesis, the reporter is expressed in extraembryonic structures, such as the chorion and amnion ( Figure 2A ). Cardiac expression is first seen in the linear heart tube at E8.0 ( Figure 2B-2D ). Expression seems to be within the heart tube and in the venous poles ( Figure 2D ). At this age, and for the next 2 days, expression is strikingly specific to the cardiovascular system. Expression continues as the heart tube undergoes looping at E8.5 ( Figure 2E and 2F) and is seen in all 4 chambers of the looped heart at E9.5 ( Figure 2G and 2H) and at E10.5 ( Figure 2I-2K ). Cardiac expression persists until at least E15.5, and at this stage the reporter is seen to be expressed throughout the myocardium, including the ventricles, atria, and the interventricular septum ( Figure 3E ). Neural expression is seen in the spinal cord beginning at E10.5 ( Figure 2I -2J) and in the midbrain at E11.5 ( Figure 2L-2N ).
To verify that β-galactosidase expression is accurately reporting the expression of Hic2, we performed (20) 12 (6) 10 (5) 10 (5) 8 (4) Distal deletions including HIC2 33 61 (20) 30 (10) 12 (4) 9 (3) 6 (2) 9 (3) Distal deletions with an LCR-D break excluding HIC2 7 86 (6) 86 (6) 14 (1) 29 (2) 29 (2) 0 Deletions distal to LCR-E 9 22 (2)* 11 (1) 22 (2) 22 (2) 11 (1) 0 Summary of all D-22q11DS cases in the literature. Data give the frequency of a disease phenotype followed by the absolute number of cases in parentheses. A complete list of all cases used to generate these data together with references is provided in Online Table I . The exact breakpoint within LCR-D has not been reported for 11 cases and thus the HIC2 genotype is ambiguous in these patients. ASD indicates atrial septal defect; CAT, common arterial trunk; D-22q11DS, distal variant of 22q11 deletion syndrome; LCR, low-copy repeat; PDA, persistent ductus arteriosus; and VSD, ventricular septal defect.
*The frequency of occurrence of any cardiac defect is significantly different between deletions with a breakpoint in LCR-D versus those with a breakpoint distal to LCR-E (Fisher exact test, 2 tailed, P=0.03). Hic2 is expressed in the developing heart throughout morphogenesis. X-gal staining of Hic2 GT/+ embryos (A-N). At E7.5 (A), before heart tube (HT) formation, LacZ expression is seen in the amnion (AM) and chorion (CH). At the linear HT stage (E8.0; B and C), LacZ is specific to the heart (arrow) and venous limbs. A transverse section of this embryo (D) shows expression in the HT (arrows) but not in gut (G) or neural plate (NP). As the heart begins to loop at E8.5 (E), LacZ expression remains specific to the heart (arrow) and venous limbs. Transverse sections (F) show expression in both future ventricles (arrows). In the looped heart at E9.5 (G), LacZ expression remains confined to the heart (arrow). The embryo shown in H has been dissected to remove the head and tail allowing a ventral view of the heart; this reveals LacZ expression in all cardiac chambers and in the outflow tract (OT). By E10.5 (I and J), LacZ is expressed in the ventral part of the spinal cord (S) in addition to the heart (arrow). A transverse section of the E10.5 heart (K) shows expression (arrows) in right ventricle (RV), left ventricle (LV), right atrium (RA), and OT. The left atrium (LA) is not shown on the section. At E11.5 (L-N), LacZ persists in the heart (arrow) and spinal cord (s); in addition, a low level of expression is seen in the midbrain (MB). Immunofluorescence on cryosections (O-T). A pan-HIC antibody (red) reveals HIC1/2 expression in an E10.0 heterozygote (O) in the atria (AT), ventricle (V), S, and musculature (somatic; M). This reflects the additive expression of HIC1 and HIC2. HIC2 (red) is expressed throughout the heart at E13.5 (P). Q, An enlarged view of the LV showing HIC2 expression in ventricle wall. HIC2 (red) is coexpressed with C-terminal binding protein (CTBP1) (green), a known cofactor of HIC1, in the heart of an E9.5 embryo (R-T, arrows) and is not expressed in the erythrocytes (*) within the center of the heart. Reverse transcriptase-quantitative polymerase chain reaction from isolated cardiac tissue (U). Hic2 mRNA is expressed in the heart at only a moderate level. The expression level is significantly reduced between E9.5 and E13.5 (t test, P=0.01).
immunohistofluorescence using both a pan-HIC antibody (Online Figure I ) and a Hic2-specific antibody. Expression of Hic1 in midgestation is largely restricted to the somites but absent from the heart and spinal cord, 24 whereas HIC1/2 immunoreactivity at E10.0 was observed in the heart and in the ventral spinal cord in addition to the somitic musculature ( Figure 2O ), thus reflecting the additive expression of Hic1+Hic2 and confirming the reporter expression ( Figure 2I ). Hic2-specific immunostaining was observed in the heart at both E13.5 ( Figure 2P and 2Q) and E9.5 ( Figure 2R-T) . At E13.5, Hic2 seems to be expressed throughout the myocardium but is concentrated at specific points ( Figure 2Q, arrows) . We observed coexpression of Hic2 with the Hic1 cofactor C-terminal binding protein (Ctbp1) in the myocardium at E9.5 ( Figure 2R-2T) .
To verify Hic2 expression in the heart further, we performed reverse transcriptase-quantitative polymerase chain reaction on isolated hearts from E9.5 and E13.5 embryos ( Figure 2U ). Hic2 expression is detectable at these time points and shows a significant decrease between E9.5 and E13.5 ( Figure 2U ).
Hic2 Has a Haploinsufficient Cardiovascular Phenotype
We interbred Hic2 GT/+ animals to obtain homozygous Hic2
GT/GT embryos. These animals showed a background-dependent embryonic lethality. No live embryos were recovered after E9.5 on a C57BL6 background, whereas they survived until day 10.5 on a CD1 background ( Figure 3A) . Embryos recovered at this age seemed developmentally delayed by about 1 day but had a morphologically normal heart tube ( Figure 3B and 3C ), suggesting that lethality may be because of an extracardiac effect. A partially penetrant heterozygous lethality was observed on the C57BL/6 but not on the CD1 background. Heterozygote embryos were recovered in the expected ratios in litters up to E15.5 but by weaning at postnatal day 21 exhibited a 31% lethality ( Figure 3D ). We hypothesized that this lethality may be because of a cardiac defect associated with the switch from maternal to pulmonary circulation at birth.
Examination of serial sections of the hearts of E15.5 heterozygous animals revealed cardiovascular defects at a frequency similar to the observed perinatal lethality. A total of 36.5% of Hic2 +/GT animals had a VSD with 28% also having an overriding aorta ( Figure 3F ; Table 2 ) indicating both a septation and misalignment defect. A minority of animals had a second VSD in the muscular portion of the septum ( Figure 3G) . A thin myocardial and trabecular layers were observed in some hearts ( Figure 3F and 3G, arrows) . To confirm these findings, we imaged hearts using optical projection tomography (Online Movie I) and MRI. Three-dimensional reconstructions of the MRI images confirmed misalignment of the aorta (Figure 3H GT/+ cross on a C57/BL6 background. C, Hic +/+ (blue bars) and Hic2 GT/+ (gray bars) embryos are recovered in the expected 50:50 ratio up to E15.5, but by P21 a highly significant 31% heterozygous lethality is seen (exact binomial test, P=0.000047). E-G, Transverse sections of E15.5 Hic2
GT/+ hearts stained with X-gal, counterstained with eosin. The heart in E has a normal anatomy, that in F a membranous ventricular septal defect (VSD), and that in G a muscular VSD. H and I, Three-dimensional reconstructions of cardiac anatomy based on MRI imaging. Both embryos are heterozygotes (GT/+). The embryo on the left has normal anatomy in which the septum is fully developed and there is no connection between the ventricles (right ventricle [RV] and left ventricle [LV] ). The main pulmonary artery (MPA) leaves the RV and is connected via the ductus arteriosus (DA) to the aorta (A), which leaves the LV. The great vessels have developed normally. The embryo on the right has a VSD and a connection between the ventricles is seen. The A opens directly above the VSD, a condition known as over-riding aorta (OA). The great vessels have developed normally. For statistical significance, *P<0.05, **P≤0.005, and ***P≤0.0005. GT indicates β-galactosidase; LCA, left carotid artery; LSA, left subclavian artery; RCA, right carotid artery; RSA, right subclavian artery; and T, trachea. and 3I). There were no pharyngeal arch artery abnormalities at E10.5 and no great vessel defects at E15.5 ( Figure 3H and 3I). We did not observe ASD or CAT in these embryos; we could not assay persistent DA because closure of the DA occurs after birth and thus the DA was patent in these embryos as expected.
Conditional Mutagenesis Confirms a Requirement for Hic2 in Cardiac Development
To characterize the Hic2 phenotype further, we generated a conditional genetrap allele, Hic2
FL
. The genetrap cassette is flanked by 2 pairs of variant LoxP sites (LoxP and Lox511) and 2 pairs of variant flippase recognition target sites (FRT and F3). Variant sites contain the same palindromic sequence but differ in the spacer such that they are incompatible 30 and are in reverse orientations on either side of the cassette. This technology, known as the FLEx switch, 31 is designed to allow irreversible rotation of the genetrap cassette. Recombination between 2 variant sites in reverse orientation rotates the genetrap but leaves the other 2 variant sites in the same orientation on 1 side of the genetrap resulting in an excision event removing the possibility of a second rotation with the same enzyme. The genetrap can be recombined in this way twice, once with flippase (FLP) and once with CRE.
The Hic FL allele in its original configuration behaves as a standard genetrap allele in which β-galactosidase is expressed in place of Hic2 exons 2 and 3 ( Figure 1A ). For clarity, we will refer to this unrecombined version of the allele as Hic2 Figure 1A) . We refer to this allele, which has been recombined once as Hic FL . The resulting mice were viable and fertile as homozygotes (Hic2
FL/FL
) and had no cardiac defects (n=8; Table 2; Figure 4L ), demonstrating that the inverted trap cassette has no substantial effect on gene function. As inversion occurs in the germline, the recombined allele is transmitted to the progeny of these mice.
Breeding the Hic FL mouse to lines expressing Cre recombinases results in inversion of the genetrap for a second time, activating the splice acceptor and resulting in a Hic2 tissuespecific null allele ( Figure 1A ). We first crossed Hic2 FL to a ubiquitously expressed Cre, ActB Cre . Knockout embryos were recovered in the expected numbers up to E9.5 but exhibited a 54% mortality by E12.5. Thus, the phenotype is less severe than either the Hic2 GT/GT or Hic2 FL-U/FL-U genotypes, perhaps reflecting inefficient recombination of the genetrap.
Turning to the tissue specificity of Hic2, we first used a Wnt1
Cre driver 32 to study a requirement for Hic2 in the neural crest, but these results were negative. The expected number of homozygous knockout offspring was obtained at 3 weeks of age, indicating that there is no embryonic or perinatal lethality in this line. We did not examine the hearts of these animals.
Targeting with an Nkx2.5 Cre driver results in mutation within the cardiomyocyte, outflow tract, and arch artery endothelial lineages from the cardiac crescent stage of heart development.
33

Nkx2.5
Cre -positive cells also contribute to the epithelia and smooth muscle of the great arteries 34 but not to the endocardial cushions or neural crest lineage. The majority of Nkx2.5
Cre ;
Hic2
FL/FL embryos exhibited no gross external abnormalities, but 19% exhibited a mild developmental delay associated with hemorrhaging ( Figure 4B and 4C) . No embryonic lethality was observed up to E15.5. We did not observe edema in these embryos. We studied the hearts of these embryos by serial sectioning, which revealed that 80% exhibited VSD with an over-riding aorta (Figure 4M and 4N ; Table 2 ). We also noted an unusually thin myocardium in 40% of embryos ( Figure 4N, arrow) .
Targeting with a Mesp1
Cre driver results in mutation within the anterior mesoderm (including cardiac progenitor cell populations). 35 
Mesp1
Cre ; Hic2 FL/FL embryos exhibited 26% mortality by E13.5, rising to 78% by P21. Most of the lethality seemed to occur in late gestation because knockout embryos seemed grossly normal until E10.5, whereas recently deceased embryos were recovered in litters at E13.5 and E15.5. Many live embryos recovered at E13.5 and exhibited phenotypes indicative of poor circulation. A total of 20% had edema ( Figure 4E and 4F), whereas 40% exhibited hemorrhaging ( Figure 4D-4F ). The hearts of those embryos recovered alive at E15.5 were examined by serial sectioning revealing a 69% incidence of VSD, often with an over-riding aorta, whereas 38% had a thin myocardium (Figure 4G-4K ; Table 2 ; Online Movie II). Although it is difficult to assign ASD at this age definitively because the atrial septum is open before birth, we noted that the atrial septae were often short in these embryos suggesting a possible ASD ( Figure 4G and 4H) .
Targeting with a transgenic Mef2c Cre driver results in mutation within the second heart field lineage comprising endothelial and myocardial components of the outflow tract, right ventricle, and ventricular septum. 36 
Mef2c
Cre ; Hic2 FL/FL embryos did not exhibit an external phenotype or embryonic lethality. We examined 3 hearts, none of which had a VSD ( Figure 4O and 4P) .
Together, these data suggest that Hic2 is required in cardiomyocytes derived from the primary heart field. We found no evidence of a requirement for Hic2 in the either secondary field or neural crest although we cannot rule out a requirement here. We did not observe a heterozygote phenotype for any conditional allele, most likely because of the inefficient recombination of the locus noted above.
Loss of Hic2 Results in Upregulation of Ectopic Gene Expression
To understand the function of Hic2 in the developing heart, we performed a microarray screen at E13. 5 . This line was chosen for analysis because it shows the most severe cardiac phenotype. Only live embryos were used in this experiment, and all hearts seemed grossly structurally intact at time of dissection. Screening revealed 284 significantly changed genes, of which 170 were upregulated (Online Table II) .
For further analysis, we made the assumption that genes with a proven role in heart development would be most likely to account for the observed Hic2 pathology and so first selected genes with a published embryonic lethal cardiac phenotype, a total of 7 genes. Reverse transcriptase-quantitative polymerase chain reaction analysis did not verify expression changes for those cardiac lethal genes with a downregulated expression: Wnt2, Aplnr, Slc4a1, and Angpt1 (data not shown).
Bmp10 was significantly upregulated relative to Mesp1
Cre controls, indicating that heterozygosity for Mesp1 cannot account for the change. Adm and Tmem100 also showed a trend toward upregulation, below the threshold for significance.
Building on this finding, we then selected several genes showing a robust upregulation on the microarray. All of these showed the same upregulation trend by quantitative polymerase chain reaction, and Kcne1 was significantly changed ( Figure 5 ). Thus our data suggest that Hic2 acts in the heart to repress a program of gene regulation. This is consistent with our finding that Hic2 colocalizes with the repressive cofactor Ctbp1 in the heart ( Figure 2R) , and a previous report indicating Hic2 is a direct transcriptional repressor.
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Discussion
There is a growing consensus in the field that D-22q11DS is a distinct clinical entity from 22q11DS. 7, 9, 28 Although there is overlap in the clinical features, there are also clear differences in the disease spectrum, such as the absence of great vessel defects in the distal disease.
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D-22q11DS most commonly results from deletions with a proximal breakpoint at LCR-D and distal at LCR-E or LCR-F. This region does not include TBX1, the only 22q11 gene with a known haploinsufficient cardiac phenotype, and suggests that haploinsufficiency of a different gene (or genes) is responsible for the atypical deletion phenotype. We have provided evidence from mouse genetics to show that HIC2 is a second haploinsufficient 22q11 gene with a cardiac phenotype.
Genetic interactions may be important in the cause of this disease, and hemizygosity for ≥2 genes in the deleted interval may contribute to the phenotype. 16 Our analysis of published cases indicates that ≥1 gene with the LCR-D/E interval in addition to HIC2 contributes to the disease. MAPK1 (400 kb distal to HIC2) has been proposed as a candidate. Targeting of Mapk1 in the neural crest demonstrated VSD with a 40% penetrance, 17 but the case for a Mapk1 haploinsufficient phenotype is ambiguous. No haploinsufficiency was observed for the Wnt1 CRE conditional allele, 17 yet heterozygosity for the null allele results in a partially penetrant lethality. 37 Whether this lethality results from cardiac defects has not been explored. In addition, heterozygosity for Mapk1 has been reported to rescue the ventricular noncompaction phenotype of Ptpn11 mice, 38 indicating a gene dosage effect. Interestingly, our conditional mutagenesis data suggest that Hic2 most likely acts within the primary heart field lineage, that is to say, the overlap between the Mesp1 and Nkx2.5 lineages. We found no evidence for a role in neural crest. Thus, it would seem that 2 different cell populations contribute to the D-22q11DS phenotype. Definitive proof of the relative contributions of HIC2 and MAPK1 would require the generation of a mouse model of D-22q11DS analogous to the Df1 model of 22q11DS, 11 in which transgenic rescue experiments could be performed.
Hic2 is thought to have 2 independent transcriptional repressor activities. It contains a BTB (Broad-Complex, Tramtrack and Bric a brac) domain, which acts as an autonomous repression domain 21 and also shares with Hic1 the GLDLSKK/R motif, which recruits the corepressor Ctbp1. 39 Our data support the hypothesis that Hic2 acts as a transcriptional repressor in the heart, interacting with Ctbp1 ( Figure 2R ) and acting to inhibit expression of a program of gene expression. For example, in the Hic2 conditional knockout, we see upregulation of skeletal muscle troponin, Tnnt3. The heart normally expresses only a single troponin T, and transgenic coexpression of Tnnt3 in the mouse heart has been shown to reduce contractile function. 40 In contrast, Bmp10 is required for cardiac development and has been shown to be required for normal trabeculation. 41 Loss of the inhibitory Smad6-which increases bone morphogenetic protein (BMP) signaling in the heart-results in hyperplastic valves and a failure in outflow tract septation. 42 Thus, both gain and loss of BMP signaling result in cardiovascular defects, suggesting that Hic2 may function to regulate the level of Bmp10 in the heart. Tmem100, also changed in our screen, is downstream of Bmp10 and is required in arterial endothelium. 43 Taken together, the human genetic and mouse genetic evidence implicate the transcription factor HIC2 as a contributor to the atypical 22q11DS phenotype. However, we do not discount the possibility of a combined haploinsufficiency of HIC2 with any or all of TBX1, CRKL, and MAPK1, depending on the size of the deletion. This could be studied in man using an international cohort designed to examine TBX1 interactions. 44 We recommend that HIC2 should be specifically considered as a predisposing locus in exome sequence studies of patients with congenital heart defects.
